Literature DB >> 26193064

Risk factors for 30-day readmission among patients with culture-positive severe sepsis and septic shock: A retrospective cohort study.

Marya D Zilberberg1,2, Andrew F Shorr3, Scott T Micek4, Marin H Kollef5.   

Abstract

BACKGROUND: With decreasing mortality in sepsis, attention has shifted to longer-term consequences associated with survivorship. Thirty-day readmission as a component of healthcare utilization is an important outcome.
OBJECTIVE: To examine the frequency of and risk factors for 30-day readmission among patients surviving sepsis.
DESIGN: Single-center retrospective cohort. METHODS/
SETTING: We examined 30-day readmission risk among survivors of hospitalization with culture-positive severe sepsis or septic shock. Extended spectrum β-lactamase (ESBL) organisms were identified via molecular laboratory testing. Healthcare-associated (HCA) was defined by 1 of the following: (1) recent hospitalization, (2) immune suppression, (3) nursing home residence, (4) hemodialysis, (5) prior antibiotics, and (6) index bacteremia hospital-acquired (onset >2 days following admission). Acute kidney injury (AKI) was defined according to the RIFLE (Risk, Injury, Failure, Loss, End-stage) criteria. Logistic regression modeled predictors of 30-day readmission.
RESULTS: Among 1697 sepsis survivors, 543 (32.0%) required 30-day readmission. Readmitted patients had a higher chronic (median Charlson score 5 vs 4, P < 0.001) but not acute (median APACHE [Acute Physiology and Chronic Health Evaluation] II score 15 and 15, P = 0.275) illness burden, and higher prevalence of HCA sepsis (94.2% vs 90.2%, P = 0.014) than nonreadmitted survivors. In logistic regression, 3 factors increased (Organism: ESBL [odds ratio {OR}: 4.50, 95% confidence interval {CI}: 1.43-14.19], RIFLE: Injury or RIFLE: Failure [OR: 1.95, 95% CI: 1.300-2.93], and Organism: Bacteroides spp [OR: 2.04, 95% CI: 1.06-3.95]) and 2 reduced ( SOURCE: Urine [OR: 0.58, 95% CI: 0.35-0.98], Organism: Escherichia coli [OR: 0.49, 95% CI: 0.27-0.90]) the odds of 30-day readmission.
CONCLUSIONS: One-third of survivors of severe sepsis/septic shock required 30-day readmission. Mild-to-moderate AKI nearly doubled its risk.
© 2015 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26193064     DOI: 10.1002/jhm.2420

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  6 in total

1.  Thirty-day hospital readmissions among mechanically ventilated emergency department patients.

Authors:  David B Page; Anne M Drewry; Enyo Ablordeppey; Nicholas M Mohr; Marin H Kollef; Brian M Fuller
Journal:  Emerg Med J       Date:  2018-01-05       Impact factor: 2.740

Review 2.  Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges.

Authors:  Manu Shankar-Hari; Gordon D Rubenfeld
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

Review 3.  Why Septic Patients Remain Sick After Hospital Discharge?

Authors:  Raquel Bragante Gritte; Talita Souza-Siqueira; Rui Curi; Marcel Cerqueira Cesar Machado; Francisco Garcia Soriano
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

4.  Independent predictors for 90-day readmission of emergency department patients admitted with sepsis: a prospective cohort study.

Authors:  Peer Oscar Overgaard Stenholt; S M Osama Bin Abdullah; Rune Husås Sørensen; Finn Erland Nielsen
Journal:  BMC Infect Dis       Date:  2021-04-01       Impact factor: 3.090

5.  Predictors of Readmission Following Discharge of Patients With Gram-Negative Bacteremia: A Retrospective Cohort Study.

Authors:  Yanay Porat; Jeries Nashashibi; Itamar Poran; Mical Paul
Journal:  Open Forum Infect Dis       Date:  2021-07-12       Impact factor: 3.835

Review 6.  Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis.

Authors:  Manu Shankar-Hari; Rohit Saha; Julie Wilson; Hallie C Prescott; David Harrison; Kathryn Rowan; Gordon D Rubenfeld; Neill K J Adhikari
Journal:  Intensive Care Med       Date:  2020-01-23       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.